<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

How to Overcome EGFR TKI Resistance in NSCLC

EGFR tyrosine kinase inhibitors (TKI) including erlotinib have provided significant clinical benefit for NSCLC patients; however, this is usually the subset of those with adenocarcinoma (ADC) rather than squamous cell carcinoma (SCC), based on studies of Caucasian populations.